Vertex Pharmaceuticals Inc (NASDAQ:VRTX)
| 350.03 Delayed Data As of Dec 08 |  -3.92 / -1.11%Today’s Change | 282.21 Today|||52-Week Range 387.42 | +21.21% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $90.2B |
Company Description
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Contact Information
Vertex Pharmaceuticals, Inc. 50 Northern Avenue Boston Massachusetts 02210 |
Employees
Shareholders
| Mutual fund holders | 62.28% |
| Other institutional | 31.49% |
| Individual stakeholders | 1.07% |
Top Executives
| Reshma Kewalramani | President, Chief Executive Officer & Director |
| Stuart A. Arbuckle | Chief Operating Officer & Executive Vice President |
| Charles F. Wagner | Chief Financial Officer & Executive Vice President |
| David Matthew Altshuler | Chief Scientific Officer & EVP-Global Research |
| Mark Bunnage | Senior Vice President & Head-Research |
